ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer

Results from the first in human study of the HIF-2α inhibitor, PT2977 in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend.

Hypoxia inducible factor 2α (HIF-2α) is known to stimulate the growth of tumours via the von Hippel-Lindau (VLH) group of genes. PT2977 (also known as MK-6482) blocks the action of HIF-2α.

In this dose expansion study, a total of 55 patients with advanced RCC and who were not responding to treatment were given the HIF-2α inhibitor, PT2977. The majority of patients (62%) had already received 3 or more prior drug treatments for their RCC, representing a very heavily pretreated population with limited therapeutic options.

Efficacy in this heavily pretreated population was encouraging, with an objective response rate of 24% (all partial responses). 56% of patients achieved stable disease, and 69% had tumour shrinkage. Only 16% of patients experienced progression of RCC. The toxicity profile compares very favourably to that of cabozantanib or everolimus plus lenvatinib.

In summary, although the trial awaits further follow-up data, responses to PT2977 were generally ongoing after 50 weeks on treatment, and several patients with tumour shrinkage continued to have disease control up to 70 weeks on therapy.

Read more in UroToday here

Share this Post!


Related post

  TOP